UFM
PACB icon

Ursa Fund Management’s Pacific Biosciences PACB Stock Holding History

Ursa Fund Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200,000
Closed -$1.03M – 20
2019
Q3 		$1.03M Buy
+200,000
New +$1.12M 0.73% 10

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ursa Fund Management's PACB Position: Q4 2019 in Review

Ursa Fund Management sold out of Pacific Biosciences (PACB) in Q4 2019, closing a stake of 200,000 shares — an estimated $1.03M sold.

Ursa Fund Management first reported a position in PACB in Q3 2019 and held it in 1 quarter. The position peaked at $1.03M in Q3 2019. 143 funds tracked by Wall St. Rank hold PACB as of Q4 2019.

  • Ursa Fund Management reported no remaining Pacific Biosciences position as of Q4 2019 after selling out during the quarter.
  • Ursa Fund Management sold 200,000 Pacific Biosciences shares in Q4 2019, an estimated $1.03M.
  • Ursa Fund Management first reported a position in Pacific Biosciences in Q3 2019 and held it in 1 quarter.
  • Ursa Fund Management's Pacific Biosciences position peaked at $1.03M in Q3 2019.
  • 143 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2019.

Based on Ursa Fund Management's 13F filing for Q4 2019, filed 29 Jan 2020.